Skip to content
10-Q

Quarterly Report

Protara Therapeutics, Inc. TARA

0001213900-25-040811

← back to feed
Filed
May 8, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 1, 2025 38.58M sh
Cash And Equivalents Q1 2025 · Mar 31, 2025 $91.46M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $162.8M
Current Liabilities Q1 2025 · Mar 31, 2025 $7.02M
Current Liabilities Q1 2025 · Dec 31, 2024 $10.96M
Total Liabilities Q1 2025 · Mar 31, 2025 $10.08M
Total Liabilities Q1 2025 · Dec 31, 2024 $14.32M
Current Assets Q1 2025 · Mar 31, 2025 $126.53M
Current Assets Q1 2025 · Dec 31, 2024 $172.16M
Total Assets Q1 2025 · Mar 31, 2025 $168.56M
Total Assets Q1 2025 · Dec 31, 2024 $181.45M
Shares Diluted Q1 2025 · Mar 31, 2024 11.42M sh
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$10.38M
Stockholders Equity Q1 2025 · Mar 31, 2024 $58.41M
Stockholders Equity Q1 2025 · Dec 31, 2023 $68.32M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.97
Eps Basic Q1 2025 · Mar 31, 2024 −$0.97
Sga Expense Q1 2025 · Mar 31, 2024 $4.1M
Rd Expense Q1 2025 · Mar 31, 2024 $7.75M
Net Income Q1 2025 · Mar 31, 2024 −$11.1M
Operating Income Q1 2025 · Mar 31, 2024 −$11.85M